Advancing equitable access to innovation in breast cancer
This manuscript critically examines the challenges associated with the design and conduct of academic global breast cancer trials outside the influence of pharmaceutical companies, leveraging insights from the Breast International Group (BIG). In the past 4 decades significant declines in breast can...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-025-00768-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849764499959054336 |
|---|---|
| author | Seamus O’Reilly Ines Vaz Luis Virginie Adam Evangelia D. Razis Ander Urruticoechea Amal Arahmani Eva Carrasco Boon H. Chua Judith Bliss Carolyn Straehle Theodora Goulioti Barbro Lindholm Gustavo Werustsky Etienne Brain Philippe L. Bedard Giuseppe Curigliano Sherene Loi Shigehira Saji David Cameron |
| author_facet | Seamus O’Reilly Ines Vaz Luis Virginie Adam Evangelia D. Razis Ander Urruticoechea Amal Arahmani Eva Carrasco Boon H. Chua Judith Bliss Carolyn Straehle Theodora Goulioti Barbro Lindholm Gustavo Werustsky Etienne Brain Philippe L. Bedard Giuseppe Curigliano Sherene Loi Shigehira Saji David Cameron |
| author_sort | Seamus O’Reilly |
| collection | DOAJ |
| description | This manuscript critically examines the challenges associated with the design and conduct of academic global breast cancer trials outside the influence of pharmaceutical companies, leveraging insights from the Breast International Group (BIG). In the past 4 decades significant declines in breast cancer mortality have occurred, partly related to industry-academic clinical and translational partnerships with long term study follow up. However, in the past decade these partnerships have largely uncoupled. The increasing complexity and non-alignment of trials, funding constraints, regulatory complexity, declining academic freedom, lack of transparency, and lack of affordability of new agents have become key barriers to equitably improving cancer outcomes. Industry research expenditure in the United States is now 5 fold greater than publically funded academic research. To address these challenges, we advocate for patient centred systemic reforms, with trials balancing commercial interests with public health imperatives. These reforms should include equitable research funding models, streamlined international clinical trial regulatory processes, and increased collaboration across diverse stakeholders. Practical solutions to enhance global trial accessibility and efficacy include leveraging digital technologies, artificial intelligence, real world data, decentralizing clinical trial infrastructure, and embedding translational research frameworks across countries. |
| format | Article |
| id | doaj-art-5133b99f80e7495b9ea244615d96a2d4 |
| institution | DOAJ |
| issn | 2374-4677 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj-art-5133b99f80e7495b9ea244615d96a2d42025-08-20T03:05:07ZengNature Portfolionpj Breast Cancer2374-46772025-07-0111111010.1038/s41523-025-00768-1Advancing equitable access to innovation in breast cancerSeamus O’Reilly0Ines Vaz Luis1Virginie Adam2Evangelia D. Razis3Ander Urruticoechea4Amal Arahmani5Eva Carrasco6Boon H. Chua7Judith Bliss8Carolyn Straehle9Theodora Goulioti10Barbro Lindholm11Gustavo Werustsky12Etienne Brain13Philippe L. Bedard14Giuseppe Curigliano15Sherene Loi16Shigehira Saji17David Cameron18Cancer Trials Ireland, Royal College of SurgeonsInstitute Gustave RoussyBreast International Group3rd Oncology Department, Hygeia HospitalR&D department, Fundación OnkologikoaBreast International GroupGEICAM Spanish Breast Cancer Group, Av de Los Pinneos. 28703 San Sebastian de los ReyesFaculty of Medicine and Health, University of New South WalesThe Institute of Cancer Research, ICR_CTSUBreast International GroupBreast International GroupInstitution of Clinical Sciences, Dept of Oncology, Sahlgrenska Academy at Gothenburg UniversityLatin American Cooperative Oncology GroupInstitut Curie-Hôpital Rene HugueninDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of TorontoEarly Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, IRCCSSir Peter MacCallum Department of Oncology, University of MelbourneDepartment of Medical Oncology, Fukushima Medical UniversityUniversity of Edinburgh Cancer Center, Western General Hospital, EDINBURGH United KingdomThis manuscript critically examines the challenges associated with the design and conduct of academic global breast cancer trials outside the influence of pharmaceutical companies, leveraging insights from the Breast International Group (BIG). In the past 4 decades significant declines in breast cancer mortality have occurred, partly related to industry-academic clinical and translational partnerships with long term study follow up. However, in the past decade these partnerships have largely uncoupled. The increasing complexity and non-alignment of trials, funding constraints, regulatory complexity, declining academic freedom, lack of transparency, and lack of affordability of new agents have become key barriers to equitably improving cancer outcomes. Industry research expenditure in the United States is now 5 fold greater than publically funded academic research. To address these challenges, we advocate for patient centred systemic reforms, with trials balancing commercial interests with public health imperatives. These reforms should include equitable research funding models, streamlined international clinical trial regulatory processes, and increased collaboration across diverse stakeholders. Practical solutions to enhance global trial accessibility and efficacy include leveraging digital technologies, artificial intelligence, real world data, decentralizing clinical trial infrastructure, and embedding translational research frameworks across countries.https://doi.org/10.1038/s41523-025-00768-1 |
| spellingShingle | Seamus O’Reilly Ines Vaz Luis Virginie Adam Evangelia D. Razis Ander Urruticoechea Amal Arahmani Eva Carrasco Boon H. Chua Judith Bliss Carolyn Straehle Theodora Goulioti Barbro Lindholm Gustavo Werustsky Etienne Brain Philippe L. Bedard Giuseppe Curigliano Sherene Loi Shigehira Saji David Cameron Advancing equitable access to innovation in breast cancer npj Breast Cancer |
| title | Advancing equitable access to innovation in breast cancer |
| title_full | Advancing equitable access to innovation in breast cancer |
| title_fullStr | Advancing equitable access to innovation in breast cancer |
| title_full_unstemmed | Advancing equitable access to innovation in breast cancer |
| title_short | Advancing equitable access to innovation in breast cancer |
| title_sort | advancing equitable access to innovation in breast cancer |
| url | https://doi.org/10.1038/s41523-025-00768-1 |
| work_keys_str_mv | AT seamusoreilly advancingequitableaccesstoinnovationinbreastcancer AT inesvazluis advancingequitableaccesstoinnovationinbreastcancer AT virginieadam advancingequitableaccesstoinnovationinbreastcancer AT evangeliadrazis advancingequitableaccesstoinnovationinbreastcancer AT anderurruticoechea advancingequitableaccesstoinnovationinbreastcancer AT amalarahmani advancingequitableaccesstoinnovationinbreastcancer AT evacarrasco advancingequitableaccesstoinnovationinbreastcancer AT boonhchua advancingequitableaccesstoinnovationinbreastcancer AT judithbliss advancingequitableaccesstoinnovationinbreastcancer AT carolynstraehle advancingequitableaccesstoinnovationinbreastcancer AT theodoragoulioti advancingequitableaccesstoinnovationinbreastcancer AT barbrolindholm advancingequitableaccesstoinnovationinbreastcancer AT gustavowerustsky advancingequitableaccesstoinnovationinbreastcancer AT etiennebrain advancingequitableaccesstoinnovationinbreastcancer AT philippelbedard advancingequitableaccesstoinnovationinbreastcancer AT giuseppecurigliano advancingequitableaccesstoinnovationinbreastcancer AT shereneloi advancingequitableaccesstoinnovationinbreastcancer AT shigehirasaji advancingequitableaccesstoinnovationinbreastcancer AT davidcameron advancingequitableaccesstoinnovationinbreastcancer |